“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”
The US dietary supplement market, from the Food and Drug Administration’s perspective, isn’t the market that was available when the framework for the agency’s regulation of the industry was established in 1994.
And the FDA doesn’t expect to effectively regulate the market with a 1994 model regulatory toolbox.
Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.
White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.
The agency says items on its Human Foods Program’s proposed agenda for guidance “to complete during 2025” include identity and safety information for NDI notifications. Its announcement also links to document about a separate key industry question, a rulemaking which would recognize NAC as a lawful
FTC decision, says Bureau of Competition director Daniel Guarnera, influenced by both companies marketing different lines in different countries, limiting the number of similar products in the same categories the combined firm would offer.
